vs
CORCEPT THERAPEUTICS INC（CORT）与福尼克斯（PLAB）财务数据对比。点击上方公司名可切换其他公司
福尼克斯的季度营收约是CORCEPT THERAPEUTICS INC的1.0倍（$210.4M vs $202.1M），CORCEPT THERAPEUTICS INC净利率更高（12.0% vs 10.9%，领先1.1%），CORCEPT THERAPEUTICS INC同比增速更快（11.1% vs -5.5%），CORCEPT THERAPEUTICS INC自由现金流更多（$38.4M vs $25.2M），过去两年CORCEPT THERAPEUTICS INC的营收复合增速更高（17.3% vs -3.8%）
Corcept Therapeutics是一家制药企业，专注于严重代谢疾病、精神疾病及肿瘤疾病治疗药物的发现、开发与商业化。公司围绕皮质醇过量带来的不良影响展开研究，致力于开发可缓解相关症状的新型化合物，管理团队由首席执行官兼总裁、董事Joseph K. Belanoff医学博士领导。
福尼克斯是美国半导体光掩模制造商，2009年时位居全球第三大光掩模供应商，同时也是电子束产业倡议组织的成员，专注于为半导体行业提供关键的掩模产品，支撑芯片制造环节的图形转移需求。
CORT vs PLAB — 直观对比
营收规模更大
PLAB
是对方的1.0倍
$202.1M
营收增速更快
CORT
高出16.6%
-5.5%
净利率更高
CORT
高出1.1%
10.9%
自由现金流更多
CORT
多$13.2M
$25.2M
两年增速更快
CORT
近两年复合增速
-3.8%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $202.1M | $210.4M |
| 净利润 | $24.3M | $22.9M |
| 毛利率 | 98.7% | 33.7% |
| 营业利润率 | 2.2% | 22.9% |
| 净利率 | 12.0% | 10.9% |
| 营收同比 | 11.1% | -5.5% |
| 净利润同比 | -21.0% | -32.4% |
| 每股收益（稀释后） | $0.20 | $0.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CORTPLAB
| Q4 25 | $202.1M | — | ||
| Q3 25 | $207.6M | $210.4M | ||
| Q2 25 | $194.4M | $211.0M | ||
| Q1 25 | $157.2M | $212.1M | ||
| Q4 24 | $181.9M | $222.6M | ||
| Q3 24 | $182.5M | $211.0M | ||
| Q2 24 | $163.8M | $217.0M | ||
| Q1 24 | $146.8M | $216.3M |
净利润CORTPLAB
| Q4 25 | $24.3M | — | ||
| Q3 25 | $19.7M | $22.9M | ||
| Q2 25 | $35.1M | $8.9M | ||
| Q1 25 | $20.5M | $42.9M | ||
| Q4 24 | $30.7M | $33.9M | ||
| Q3 24 | $47.2M | $34.4M | ||
| Q2 24 | $35.5M | $36.3M | ||
| Q1 24 | $27.8M | $26.2M |
毛利率CORTPLAB
| Q4 25 | 98.7% | — | ||
| Q3 25 | 97.8% | 33.7% | ||
| Q2 25 | 98.2% | 36.9% | ||
| Q1 25 | 98.5% | 35.6% | ||
| Q4 24 | 98.4% | 37.0% | ||
| Q3 24 | 98.4% | 35.6% | ||
| Q2 24 | 98.5% | 36.5% | ||
| Q1 24 | 98.3% | 36.6% |
营业利润率CORTPLAB
| Q4 25 | 2.2% | — | ||
| Q3 25 | 4.9% | 22.9% | ||
| Q2 25 | 13.7% | 26.4% | ||
| Q1 25 | 2.2% | 24.6% | ||
| Q4 24 | 13.9% | 25.1% | ||
| Q3 24 | 25.5% | 24.7% | ||
| Q2 24 | 21.7% | 25.8% | ||
| Q1 24 | 20.1% | 26.6% |
净利率CORTPLAB
| Q4 25 | 12.0% | — | ||
| Q3 25 | 9.5% | 10.9% | ||
| Q2 25 | 18.1% | 4.2% | ||
| Q1 25 | 13.1% | 20.2% | ||
| Q4 24 | 16.9% | 15.2% | ||
| Q3 24 | 25.9% | 16.3% | ||
| Q2 24 | 21.7% | 16.7% | ||
| Q1 24 | 18.9% | 12.1% |
每股收益（稀释后）CORTPLAB
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.16 | $0.39 | ||
| Q2 25 | $0.29 | $0.15 | ||
| Q1 25 | $0.17 | $0.68 | ||
| Q4 24 | $0.25 | $0.54 | ||
| Q3 24 | $0.41 | $0.55 | ||
| Q2 24 | $0.32 | $0.58 | ||
| Q1 24 | $0.25 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $372.2M | $575.8M |
| 总债务越低越好 | — | $16.0K |
| 股东权益账面价值 | $647.8M | $1.1B |
| 总资产 | $836.7M | $1.8B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资CORTPLAB
| Q4 25 | $372.2M | — | ||
| Q3 25 | $421.7M | $575.8M | ||
| Q2 25 | $342.2M | $558.4M | ||
| Q1 25 | $322.8M | $642.2M | ||
| Q4 24 | $383.3M | $640.7M | ||
| Q3 24 | $380.3M | $606.4M | ||
| Q2 24 | $473.2M | $559.9M | ||
| Q1 24 | $410.8M | $521.5M |
总债务CORTPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $16.0K | ||
| Q2 25 | — | $19.0K | ||
| Q1 25 | — | $21.0K | ||
| Q4 24 | — | $25.0K | ||
| Q3 24 | — | $28.0K | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $2.7M |
股东权益CORTPLAB
| Q4 25 | $647.8M | — | ||
| Q3 25 | $631.9M | $1.1B | ||
| Q2 25 | $635.8M | $1.1B | ||
| Q1 25 | $683.3M | $1.1B | ||
| Q4 24 | $679.6M | $1.1B | ||
| Q3 24 | $638.8M | $1.1B | ||
| Q2 24 | $596.2M | $1.0B | ||
| Q1 24 | $547.9M | $1.0B |
总资产CORTPLAB
| Q4 25 | $836.7M | — | ||
| Q3 25 | $823.6M | $1.8B | ||
| Q2 25 | $801.7M | $1.7B | ||
| Q1 25 | $846.5M | $1.7B | ||
| Q4 24 | $840.6M | $1.7B | ||
| Q3 24 | $784.3M | $1.6B | ||
| Q2 24 | $714.6M | $1.6B | ||
| Q1 24 | $655.9M | $1.6B |
负债/权益比CORTPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.4M | $50.1M |
| 自由现金流经营现金流 - 资本支出 | $38.4M | $25.2M |
| 自由现金流率自由现金流/营收 | 19.0% | 12.0% |
| 资本支出强度资本支出/营收 | 0.0% | 11.8% |
| 现金转化率经营现金流/净利润 | 1.58× | 2.19× |
| 过去12个月自由现金流最近4个季度 | — | $64.5M |
8季度趋势，按日历期对齐
经营现金流CORTPLAB
| Q4 25 | $38.4M | — | ||
| Q3 25 | $54.5M | $50.1M | ||
| Q2 25 | $43.9M | $31.5M | ||
| Q1 25 | $5.1M | $78.5M | ||
| Q4 24 | $59.3M | $68.4M | ||
| Q3 24 | $73.8M | $75.1M | ||
| Q2 24 | $41.2M | $76.5M | ||
| Q1 24 | $23.8M | $41.5M |
自由现金流CORTPLAB
| Q4 25 | $38.4M | — | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | $43.9M | $-29.1M | ||
| Q1 25 | $5.0M | $43.3M | ||
| Q4 24 | $59.2M | $25.2M | ||
| Q3 24 | $72.2M | $50.7M | ||
| Q2 24 | $40.8M | $56.5M | ||
| Q1 24 | — | $-1.8M |
自由现金流率CORTPLAB
| Q4 25 | 19.0% | — | ||
| Q3 25 | — | 12.0% | ||
| Q2 25 | 22.6% | -13.8% | ||
| Q1 25 | 3.2% | 20.4% | ||
| Q4 24 | 32.5% | 11.3% | ||
| Q3 24 | 39.5% | 24.0% | ||
| Q2 24 | 24.9% | 26.0% | ||
| Q1 24 | — | -0.8% |
资本支出强度CORTPLAB
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 11.8% | ||
| Q2 25 | 0.0% | 28.7% | ||
| Q1 25 | 0.1% | 16.6% | ||
| Q4 24 | 0.1% | 19.4% | ||
| Q3 24 | 0.9% | 11.6% | ||
| Q2 24 | 0.3% | 9.2% | ||
| Q1 24 | 0.0% | 20.0% |
现金转化率CORTPLAB
| Q4 25 | 1.58× | — | ||
| Q3 25 | 2.77× | 2.19× | ||
| Q2 25 | 1.25× | 3.55× | ||
| Q1 25 | 0.25× | 1.83× | ||
| Q4 24 | 1.93× | 2.02× | ||
| Q3 24 | 1.56× | 2.18× | ||
| Q2 24 | 1.16× | 2.11× | ||
| Q1 24 | 0.86× | 1.59× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CORT
暂无分部数据
PLAB
| High End Integrated Circuits | $53.6M | 25% |
| High End Flat Panel Displays | $53.5M | 25% |
| KR | $43.7M | 21% |
| Other | $42.1M | 20% |
| Mainstream Flat Panel Displays | $9.1M | 4% |
| Transferred At Point In Time | $8.4M | 4% |
